Scarica l'app Stockscreener
0.7147
1.23%
-0.0089
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista? (sotagliflozin) - Marketscreener.com
Stocks to Watch: Rumble, Lexicon Pharmaceuticals - MarketWatch
FDA rejects Lexicon's Zynquista for diabetes, kidney disease - Seeking Alpha
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - The Manila Times
Lexicon Pharma Receives FDA Rejection for Diabetes Drug Zynquista, Shifts Focus to Pain Treatment Pipeline - StockTitan
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com
Point72 Asset Management L.P. Sells 2,891,141 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Fmr LLC Has $78.29 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals (LXRX) Stock Dips Amid Market Volatility - GuruFocus.com
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals stock hits 52-week low at $0.73 - Investing.com India
Braidwell LP Sells 7,493,366 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat
Lexicon completes subject enrolment for DPNP trial of LX9211 - Clinical Trials Arena
2 Generic Drug Stocks Ready to Surge in 2025 - Benzinga
The Escalator: Lexicon Pharmaceuticals, Reckitt, NIH and more - MM+M Online
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - The Manila Times
Lexicon Pharma Hits 120% Enrollment Target in Key Pain Drug Trial, Ahead of Schedule | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals to Participate in December Investor Conferences - The Manila Times
Lexicon Pharmaceuticals CEO to Present at Two Major Healthcare Conferences in December | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals shares target cut, retains buy rating on FDA letter - Investing.com UK
Lexicon pivots back to pipeline after FDA rejection - The Pharma Letter
Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Hold" Rating from Needham & Company LLC - MarketBeat
Lexicon Pharmaceuticals to cut 60% of workforce By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals to cut 60% of workforce - Investing.com India
Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown - Citeline News & Insights
Diabetes Endpoints: A1C Reduction Is ‘Still Enough,’ Just Not For Lexicon’s Sotagliflozin, US FDA Says - Citeline
Lexicon to disband sales team, lay off 60% of staff - BioPharma Dive
Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback - Reuters.com
Lexicon Pharmaceuticals to Slash 60% of Jobs, Close Commercial Operations as Part of Reorganization - MarketWatch
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - The Manila Times
Lexicon Pharma (LXRX) to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - StreetInsider.com
Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals appoints Ivan Cheung to board By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Lexicon Appoints Ivan H. Cheung to Board of Directors - The Manila Times
Lexicon Appoints Ivan Cheung to Board of Directors - citybiz
Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India
Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance
Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat
Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India
What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times
Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):